Sustanon 300 mg/ml - Royal Pharmaceuticals
Sustanon 300 by Royal Pharmaceuticals is a mixed-ester testosterone research preparation containing Testosterone Propionate (50 mg), Phenylpropionate (70 mg), Isocaproate (70 mg), and Decanoate (110 mg) per ml (total 300 mg/ml). This combination delivers both rapid and sustained testosterone release, making it a standard reference for studies on androgen signalling, pharmacokinetics, erythropoiesis and endocrine regulation. For laboratory research only — not for human or veterinary use.
€ 49.00
Descrizione
Sustanon 300 mg/ml – Royal Pharmaceuticals (Mixed-Ester Testosterone)
Categoria: Injectable Mixed-Ester Testosterone (Research Only)
Marchio: Prodotti farmaceutici reali
Strength: 300 mg/ml total testosterone
Ester Breakdown: T. Propionate 50 mg, T. Phenylpropionate 70 mg, T. Isocaproate 70 mg, T. Decanoate 110 mg
Packing: 10 fiale da 1 ml
Origine: United Kingdom
Prezzo: €49
Use Notice: For laboratory and analytical research only — not for therapeutic, performance-enhancing or veterinary use.
🧪 What Is Sustanon 300?
Sustanon 300 is a mixed-ester testosterone formulation combining fast, medium, and long-acting esters in a single intramuscular injection.
This composition creates:
- A rapid onset from short-ester testosterone propionate
- Sustained release from intermediate esters (phenylpropionate, isocaproate)
- Long-term maintenance via testosterone decanoate
Mixed-ester testosterone solutions are widely referenced in medical, pharmacological and endocrine research, particularly in the context of male hypogonadism, androgen replacement therapy and anabolic-androgenic signalling.
🔬 Key Technical Characteristics
- Pharmacological class: Anabolic-androgenic steroid (androgen receptor agonist)
- Route: Intramuscular (I.M.) only
- Release pattern: Rapid–intermediate–prolonged due to ester diversity
- Approximate effective duration: ~2–3 weeks per injection (literature-based)
- WADA status: Exogenous testosterone and all esters are prohibited at all times (S1 – Anabolic Agents)
🧬 Meccanismo d'azione
After injection, esterases gradually hydrolyse each testosterone ester, releasing free testosterone into circulation. Free testosterone:
- Binds to androgen receptors in muscle, bone and reproductive tissues
- Modulates transcription of androgen-responsive genes
- Increases protein synthesis and nitrogen retention
- Supports erythropoiesis and increases hemoglobin/hematocrit
- Aromatises to estradiol and reduces to DHT, influencing multiple hormonal pathways
📚 Ricerca e contesto clinico
- Mild–severe hypogonadism: Testosterone esters restore libido, mood, bone density and body composition.
- Pharmacokinetic research: Mixed-ester profiles provide comparative data for absorption and release rates.
- Endocrine studies: Used to evaluate HPG-axis suppression and recovery mechanisms.
- Metabolic studies: Testosterone affects insulin sensitivity, lipid profiles and muscle–fat partitioning.
Note: These refer to medical literature and do not imply suitability for non-medical use.
📈 Potential Research-Level Observations
- Increase in lean body mass and nitrogen retention
- Improved bone mineral density in hypogonadal models
- Enhanced red-blood-cell production
- Alterations in lipid profile and glucose regulation
- Clear suppression of endogenous LH/FSH signalling
⚠️ Possible Adverse Effects (Research Context)
Endocrine & Reproductive
- Suppression of LH/FSH
- Reduced endogenous testosterone
- Decreased spermatogenesis; potential infertility
Cardiovascular & Haematological
- Elevated hematocrit / polycythaemia
- Lower HDL, increased LDL
- Potential blood-pressure changes
Androgenic Effects
- Acne, pelle grassa, perdita di capelli
- Possible virilisation effects in female exposure
Hepatic & Metabolic
- Injectable esters have low intrinsic hepatotoxicity but may influence metabolic enzymes
Other
- Mood variation, irritability, aggression
- Injection-site irritation or pain
🛑 Compliance & Regulatory Notice
- Prescription-only in most jurisdictions
- Testosterone (all forms) is a prohibited WADA S1 anabolic agent
- Handling requires adherence to local laws and research regulations
📊 Technical Data Table
| Parameter | Value |
|---|---|
| Product name | Sustanon 300 mg/ml - Royal Pharmaceuticals |
| Principio attivo | Mixed testosterone esters |
| Composition | 50 mg Propionate; 70 mg Phenylpropionate; 70 mg Isocaproate; 110 mg Decanoate |
| Concentrazione | 300 mg/ml |
| Formulation | Sterile oil solution for I.M. use |
| Packing | 10 fiale da 1 ml |
| Primary class | Anabolic-androgenic steroid (AAS) |
| WADA status | Prohibited (S1 – anabolic agents) |
For laboratory and research use only — not for human or veterinary administration.
Non ci sono ancora recensioni.
